Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 801–900 of 1,001
Management and Care of Older Cardiac Patients
Damluji, A. A., Ramireddy, A., & Forman, D. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.64094-2 · Cited by 13
Kernéis, M., Ferrante, A., Guedeney, P., Vicaut, É., & Montalescot, G. (2020) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.09.002 · Cited by 10
Kim, M., Cho, Y. K., Jung, C. H., & Lee, W. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111125 · Cited by 10
Ofili, E., Cable, G., Neutel, J. M., & Saunders, E. (2008) · Journal of Women s Health · doi:10.1089/jwh.2008.0499 · Cited by 10
Cardiovascular Prevention in Subjects with Impaired Fasting Glucose or Impaired Glucose Tolerance
Volpe, M., Borghi, C., Perin, P. C., Chiariello, M., Manzato, E., Miccoli, R., Modena, M. G., Riccardi, G., Sesti, G., Tiengo, A., et al. (2010) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/11311830-000000000-00000 · Cited by 10
Novel pathways and therapies in experimental diabetic atherosclerosis
Koulis, C., de Haan, J. B., & Allen, T. J. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.13 · Cited by 10
Renin‐angiotensin system inhibition: how much is too much of a good thing?
Campbell, D. J. (2002) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2002.00286.x · Cited by 10
Primary and secondary prevention of stroke by antihypertensive drug treatment
Wang, J., & Li, Y. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.6.1023 · Cited by 10
Antihypertensive therapy and cerebrovascular protection
Volpe, M., & Tocci, G. (2006) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000242175.59823.f2 · Cited by 10
Aşkın, L., Taşolar, H., Aksu, U., Çetın, M., Uslu, A., Tanboğa, İ. H., Türkmen, S., & Aktürk, E. (2017) · Blood Pressure Monitoring · doi:10.1097/mbp.0000000000000297 · Cited by 11
Chang, Y., Fan, H., Lim, P., Chuang, S., & Hsu, C. (2020) · Diabetic Medicine · doi:10.1111/dme.14436 · Cited by 10
Lee, C., Hsieh, M., Roth, J. G., Fu, X., Lu, C., Hung, K., Kuo, C., & Liu, S. (2022) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c00186 · Cited by 11
Management of ACCF/AHA Stage A and B Patients
Subzposh, F. A., Gupta, A., Hankins, S. R., & Eisen, H. J. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.09.003 · Cited by 11
Prescribing Trends and Drug Budget Impact of the ARBs in the UK
Blak, B. T., Mullins, C. D., Shaya, F. T., Simoni, J. M., Cooke, C. E., & Weir, M. R. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00423.x · Cited by 11
Sica, D. A. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00450.x · Cited by 11
Ferdinand, K. C. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.1559-4564.2006.05487.x · Cited by 10
Tocci, G., & Volpe, M. (2011) · Drugs · doi:10.2165/11591350-000000000-00000 · Cited by 11
Role of AMPK in Diabetic Cardiovascular Complications: An Overview
Nellaiappan, K., Yerra, V. G., & Kumar, A. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180508104929 · Cited by 9
Cardiovascular Disease in Racial and Ethnic Minorities
Ferdinand, K. C., & Armani, A. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-59745-410-0 · Cited by 11
Belz, G. G. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01880.x · Cited by 10
Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus: An Update
Hovens, M. M. C., Tamsma, J. T., Beishuizen, E. D., & Huisman, M. V. (2005) · Drugs · doi:10.2165/00003495-200565040-00001 · Cited by 12
Schunkert, H., Döring, A., Kuch, B., Holmer, S. R., Luchner, A., Muscholl, M. W., Fischer, M. A. T. S., Hengstenberg, C., Riegger, G. A. J., & Hense, H. (2005) · Das Gesundheitswesen · doi:10.1055/s-2005-858247 · Cited by 11
Doggrell, S. A. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.11.1543 · Cited by 10
Ueshima, K., Oba, K., Yasuno, S., Fujimoto, A., Sato, T. S., Fukiyama, K., Azuma, J., Ogihara, T., Saruta, T., & Nakao, K. (2008) · Contemporary Clinical Trials · doi:10.1016/j.cct.2008.09.006 · Cited by 10
Fox, J. C., Leight, K., Sutradhar, S., Demopoulos, L. A., Gleim, G. W., Lewin, A. J., & Bakris, G. L. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2004.03488.x · Cited by 12
Emerging drugs for diabetic nephropathy
Bruno, S., Cattaneo, D., Perico, N., & Remuzzi, G. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.747 · Cited by 11
Erhardt, L. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10466.x · Cited by 10
Metabolic effects of antihypertensive treatment: long live the debate
Ferrannini, E., & Kozàkovà, M. (2003) · Journal of Hypertension · doi:10.1097/00004872-200308000-00007 · Cited by 11
Conventional Therapy and Newer Drug Classes for Cardiovascular Protection in Hypertension
Wang, J., & Staessen, J. A. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032488.86836.50 · Cited by 10
Nilsson, P. M., Cífková, R., & Kjeldsen, S. E. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000198038.01387.9b · Cited by 10
Self-citationEpidemiology of Type 2 Diabetes
Ronald, C. W., & Tong, P. C. Y. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch5 · Cited by 20
Gnudi, L., Fountoulakis, N., Panagiotou, A., Corcillo, A., Maltese, G., Rife, M. F., Ntalas, I. V., Franks, R., Chiribiri, A., Ayis, S. A., et al. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.03.003 · Cited by 10
Braga, J. R., Avezum, Á., Ferreira, S. R. G., & Forti, A. C. E. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-46 · Cited by 12
Qureshi, W., Nasir, K., Hacıoğlu, Y., Sibley, C. T., Gupta, M., Rivera, J. J., Blumenthal, R. S., Katz, R., & Budoff, M. J. (2015) · Journal of cardiovascular computed tomography · doi:10.1016/j.jcct.2015.01.001 · Cited by 8
Current treatment of heart failure with reduction of left ventricular ejection fraction
Aronow, W. S. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1242067 · Cited by 10
Takihata, M., Nakamura, A., Kondo, Y., Kawasaki, S., Kimura, M., & Terauchi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125519 · Cited by 10
Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study
Lake, J. E., Seang, S., Kelesidis, T., Liao, D. H., Hodis, H. N., Stein, J. H., & Currier, J. S. (2015) · HIV Clinical Trials · doi:10.1179/1945577115y.0000000006 · Cited by 9
Baldwin, M. D. (2011) · The Journal of the American Osteopathic Association · Cited by 8
Is RAS blockade routinely indicated in hypertensive kidney transplant patients?
Salzberg, D. J. (2007) · Current Hypertension Reports · doi:10.1007/s11906-007-0077-4 · Cited by 9
Matsuzaki, G., Ishizaka, N., Furuta, K., Hongo, M., Saito, K., Sakurai, R., Koike, K., & Nagai, R. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.061 · Cited by 11
Schmieder, R. E., Bramlage, P., Haller, H. G., Ruilope, L. M., & Böhm, M. (2016) · Medicine · doi:10.1097/md.0000000000003122 · Cited by 10
Fan, Q.-L., Wang, J., Zhang, S., Liu, T., Zhao, J., & You, S. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2957094 · Cited by 9
Jung, M., Choo, E., & Lee, S. (2020) · Clinical Epidemiology · doi:10.2147/clep.s265966 · Cited by 11
Mthembu, N. H., Norton, G. R., Peterson, V. R., Naran, R., Yusuf, S. M., Tade, G., Bello, H., Bamaiyi, A. J., Libhaber, C. D., Dessein, P. H., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18271 · Cited by 9
(2001) · International Journal of Educational Development · doi:10.1016/s0738-0593(01)00016-5 · Cited by 9
Beneficial effects of carvedilol modulating potassium channels on the control of glucose
Li, X. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113057 · Cited by 10
Khan, A. H., & Imig, J. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.96704-7 · Cited by 11
Feghali, R. E., Nisse-Durgeat, S., & Asmar, R. G. (2007) · PubMed Central · Cited by 12
Benefits of ACE Inhibitors in Diabetes
Ramos‐Niño, M. E., & Blumen, S. R. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2027 · Cited by 9
Caruso, D., D’Avino, M., Acampora, C., Romano, L., Bevilacqua, N., Caruso, G., Esposti, D. D., & Borghi, C. (2004) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200411000-00002 · Cited by 9
Yin, G., Lin, S., Xu, D., Sun, R.-Q., Lin, K., & Lin, C. (2013) · International Journal of Endocrinology · doi:10.1155/2013/493828 · Cited by 11
Sharman, D. C., Morris, A. D., & Struthers, A. D. (2007) · Diabetologia · doi:10.1007/s00125-007-0754-5 · Cited by 9
Angiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction
Weir, M. R. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.03473.x · Cited by 9
Protogerou, A. D., Papaioannou, T. G., Sfikakis, P. P., Blacher, J., Karatzis, E. N., Lekakis, J. P., Papadogiannis, D., Stefanadis, C., & Safar, M. E. (2011) · Artery Research · doi:10.1016/j.artres.2011.11.001 · Cited by 9
Losartan in Cardiovascular Disease
de Vogel, S., Hoorn, E. J., & Papademetriou, V. (2005) · Future Cardiology · doi:10.2217/14796678.1.4.433 · Cited by 8
Value of Angiotensin Receptor Blocker Therapy in Diabetes
Izzo, J. L., & Zion, A. S. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00447.x · Cited by 9
Therapeutic potential of angiotensin receptor blockers in hypertension
Cheung, B. M. Y. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.6.625 · Cited by 10
Épidémiologie des accidents vasculaires cérébraux : son impact dans la pratique médicale
Lemesle, M., Bénatru, I., Rouaud, O., Contegal, F., Maugras, C., Fromont, A., Moreau, T., & Giroud, M. (2006) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(06)28757-8 · Cited by 18
Two-year changes in proteinuria and risk for myocardial infarction in patients with hypertension
Wang, A., Liu, X., Su, Z., Chen, S., Zhang, N., Wang, Y., Wang, Y., & Wu, S. (2017) · Journal of Hypertension · doi:10.1097/hjh.0000000000001462 · Cited by 9
Ke, C., Morgan, S., Smolina, K., Gašević, D., Qian, H., & Khan, N. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-013808 · Cited by 9
Major, T. C., Olszewski, B., Rosebury, W. S., Okerberg, C. V., Carlson, T., Ostroski, R., Schroeder, R., Kowala, M. C., & Leadley, R. J. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6131-x · Cited by 10
Ikeda, F., Azuma, K., Ogihara, T., Toyofuku, Y., Otsuka, A., Mita, T., Hirose, T., Tanaka, Y., Kawamori, R., & Watada, H. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-004 · Cited by 9
Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes
Macfarlane, D. P., Paterson, K., & Fisher, M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00735.x · Cited by 10
Use of beta-blockers for uncomplicated hypertension in the elderly: a cause for concern
Tu, K., Campbell, N. R. C., Chen, Z., & McAlister, F. A. (2007) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1002128 · Cited by 9
Kjeldsen, S. E., Lyle, P. A., Tershakovec, A. M., Devereux, R. B., Oparil, S., Dahlöf, B., Fairé, U. D., Fyhrquist, F., Ibsen, H., Kristianson, K. J., et al. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.4.729 · Cited by 10
Self-citationOparil, S., Abate, N. I., Chen, E., Creager, M. A., Galet, V. A., Jia, G., Julius, S., Lerman, A., Lyle, P. A., Pool, J. L., et al. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x280716 · Cited by 11
Self-citationMicroalbuminuria in hypertensive patients: Evaluation of one-year treatment with irbesartan
de Álvaro, F., Velasco, O., Honorato, J., Calvo, C., & PARRONDO, I. (2004) · Kidney International · doi:10.1111/j.1523-1755.2005.09307.x · Cited by 14
Seki, N., Hashimoto, N., Suzuki, Y., Yagui, K., & Saito, Y. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.09.015 · Cited by 9
Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons
Aronow, W. S. (2005) · The Journals of Gerontology Series A · doi:10.1093/gerona/60.12.1597 · Cited by 11
Ribeiro, A. B., & Gavras, H. P. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200019 · Cited by 9
Conceptual Basis and Methodology of the SOPHIA Study
on behalf of the Study Group on Cardivascular Pharmacogenomics of the Italian Society of Hypertension, Glorioso, N., Argiolas, G., Filigheddu, F., Troffa, C., Cocco, F., Bulla, E., Bulla, P., Zaninello, R., Degortes, S., et al. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.11.1497 · Cited by 8
Townsend, R. R., Forker, A. D., Bhosekar, V., Yadao, A. M., & Keefe, D. L. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00552.x · Cited by 9
Schüler, S., Mucha, A., Doherty, P., Kieser, M., & Rauch, G. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.267 · Cited by 8
Ma, J., Wang, X., Hu, Z.-D., Zhou, Z., Schoenhagen, P., & Wang, H. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.12.39 · Cited by 10
Complex formation equilibria of Cu2+ and Zn2+ with Irbesartan and Losartan
Lachowicz, J. I., Nurchi, V. M., Crisponi, G., Jaraquemada-Peláez, M. D. G., Caltagirone, C., Peana, M., Zoroddu, M. A., Szewczuk, Z., & Cooper, G. J. S. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.11.010 · Cited by 8
Mavrakanas, T. A., & Lipman, M. L. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.006 · Cited by 9
Mehta, R., Pichel, D., Chen-Ku, C. H., Raffaele, P. M., Durán, A. M., Padilla, F., Álvarez, J. J. A., Gil, J. E. C., Gómez‐Mesa, J. E., Giorgi, M. A., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00961-4 · Cited by 13
Now or Never: Optimal Antihypertensive Therapy in the Elderly
Prisant, L. M. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00005.x · Cited by 8
ACE inhibitors or ARBs for diabetic nephropathy: The unrelenting debate
Kota, S. K., Meher, L. K., Jammula, S., Kota, S. K., & Modi, K. D. (2012) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2012.08.005 · Cited by 9
The Alphabet strategy — a tool to achieve clinical trial standards in routine practice?
Jaiveer, P. K., Jaiveer, S., Lee, J. D., Morrissey, J. R., & Patel, V. (2003) · The British Journal of Diabetes · doi:10.1177/14746514030030060401 · Cited by 8
Primary prevention of heart failure: what is the evidence?
Dupree, C. S. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283207aee · Cited by 10
Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., Yatsuji, H., Sezaki, H., Hosaka, T., Hirakawa, M., et al. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21572 · Cited by 8
Albayrak, S., Ordu, S., Özhan, H., Yazıcı, M., Aydın, M., Alemdar, R., & Kaya, A. (2009) · Blood Pressure · doi:10.1080/08037050903047236 · Cited by 8
Prevalence of proteinuria in rural adult population in Tamil Nadu.
Ahmed, I., John, G. T., Kirubakaran, M. G., Jacob, C. K., & Muliyil, J. (2006) · PubMed · Cited by 13
Rump, L. C., & Sellin, L. K. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.510834 · Cited by 8
Vascular cognitive impairment in diabetes mellitus: are prevention and treatment effective?
Zavoreo, I., Madžar, Z., Demarin, V., & Kes, V. B. (2014) · PubMed · Cited by 12
Hypertension and concomitant diseases: a guide for evidence-based therapy.
Retta, T. M., & Randall, O. S. (2004) · PubMed Central · Cited by 8
Blood pressure management in patients with type 2 diabetes mellitus
Kai, H. (2017) · Hypertension Research · doi:10.1038/hr.2017.55 · Cited by 9
Faggiano, P. M., Bernardi, N., Calvi, E., Bonelli, A., Faggiano, A., Bursi, F., & Bosisio, M. (2021) · Heart Failure Clinics · doi:10.1016/j.hfc.2021.01.004 · Cited by 11
Chronobiologically Explored Effects of Telmisartan
Prikryl, P., Cornélissen, G., Neubauer, J., Prikryl, P., Karpíšek, Z., Watanabe, Y., Otsuka, K., & Franz Halberg, A. (2005) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200048733 · Cited by 8
ESC/EASD-Leitlinien zu Diabetes und kardiovaskulären Erkrankungen
Motz, W., & Dörr, R. (2009) · Herz · doi:10.1007/s00059-009-3203-z · Cited by 12
Chavalitdhamrong, D., Danovitch, G. M., & Bunnapradist, S. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00351.x · Cited by 8
Was the LIFE trial independent?
Vandenbroucke, J. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11211-6 · Cited by 8
Recommendations for Special Populations: The Treatment of Hypertension in Diabetes Mellitus
Tan, A. S., Kuppuswamy, S., Whaley‐Connell, A. T., Kurukulasuriya, L. R., & Sowers, J. R. (2004) · The Endocrinologist · doi:10.1097/01.ten.0000146262.10013.e7 · Cited by 8
Therapeutic Controversies in Hypertension
Messerli, F. H., & Grossman, E. (2005) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2005.02.007 · Cited by 8
Bergenstal, R. M., Nag, S. S., Reusch, J. E. B., Sajjan, S. G., & Alexander, C. M. (2005) · Endocrine Practice · doi:10.4158/ep.11.3.172 · Cited by 8
A Guide to the Management of Blood Pressure in the Diabetic Hypertensive Patient
Shammas, N. W., Sica, D. A., & Toth, P. P. (2009) · American Journal of Cardiovascular Drugs · doi:10.1007/bf03256572 · Cited by 9
Villaverde, J. M. F., Saavedra, F. J. M., Vidal, G., Shamagian, L. G., Otero-Raviña, F., & González‐Juanatey, J. R. (2007) · Medicina Clínica · doi:10.1157/13106936 · Cited by 10
Prevention and Health Services Delivery
Goldstein, L. B. (2003) · Stroke · doi:10.1161/01.str.0000054668.94988.f9 · Cited by 8
Características farmacológicas de los ARA-II. ¿Son todos iguales?
Tamargo, J. L., Caballero, R., Gómez, R. J., Núñez, L., Vaquero, M., & Delpón, E. (2006) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(06)75306-7 · Cited by 10
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.